Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.CMPX · Entity 5614 | Director | January 02, 2026 | January 05, 2026 |
| Kymera Therapeutics, Inc.KYMR · Entity 3545 | Chief Legal Officer | March 03, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.17 · Expires 2036-01-02 | Direct | 90,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 90,000 · Balance 90,000 F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders.
Kymera Therapeutics, Inc.
Report date March 03, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,085 |
Ending reported balance
After 2025-03-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-03 · Grant · Acquired 27,500 · Balance 82,326 F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Row 2 · 2025-03-03 · Sale · Disposed 1,833 · Balance 80,493 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2025-03-03 · Sale · Disposed 408 · Balance 80,085 F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.17 · Expires 2035-03-02 | Direct | 55,000 |
Reported balance
After 2025-03-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-03 · Grant · Acquired 55,000 · Balance 55,000 F5: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in three equal annual installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
F2: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.90 to $30.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.90 to $31.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALERE INC.
Report date October 03, 2017 · Filed October 03, 2017
Section 16 reporting ended · disclosed 2017-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 1
1 source rowRow 1 · 2017-10-03 · Disposition to issuer · Disposed 32,764 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration"). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.58 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-03 · Disposition to issuer · Disposed 8,331 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.01 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-03 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.06 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-10-03 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.47 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-10-03 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.42 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-10-03 · Disposition to issuer · Disposed 5,250 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.43 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-10-03 · Disposition to issuer · Disposed 975 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.68 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2017-10-03 · Disposition to issuer · Disposed 11,788 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.74 | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2017-10-03 · Disposition to issuer · Disposed 1,500 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-10-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2017-10-03 · Disposition to issuer · Disposed 19,470 · Balance 0 F3: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").
F2: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.
F3: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 116,850 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,404 | Not disclosed Strike: $37.74 | Not disclosed |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · derivative · entry 10 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,404 shares Expires 2016-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This derivative security does not have a price. F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning October 16, 2007. F4 · derivative.expiration_date: The Options were scheduled to expire on October 15, 2016. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,096 | Not disclosed Strike: $37.74 | Not disclosed |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · derivative · entry 9 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,096 shares Expires 2016-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This derivative security does not have a price. F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning October 16, 2007. F4 · derivative.expiration_date: The Options were scheduled to expire on October 15, 2016. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,500 | Not disclosed Strike: $37.74 | Not disclosed |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · derivative · entry 8 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,096 Underlying: Common Stock · 3,500 shares Expires 2016-10-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: This derivative security does not have a price. F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning October 16, 2007. F4 · derivative.expiration_date: The Options were scheduled to expire on October 15, 2016. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Tax withholdingCommon Stock | 4,393 | $42.95 | $188,679.35 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 7 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,529 F3 · shares: Represents withholding of shares of Company common stock to satisfy exercise price and tax liability associated with exercise of stock options shown above. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionCommon Stock | 5,000 | $37.74 | $188,700.00 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 6 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Tax withholdingCommon Stock | 8,263 | $42.95 | $354,895.85 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 5 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,922 F3 · shares: Represents withholding of shares of Company common stock to satisfy exercise price and tax liability associated with exercise of stock options shown above. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionCommon Stock | 9,404 | $37.74 | $354,906.96 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 4 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,185 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Tax withholdingCommon Stock | 6,235 | $42.95 | $267,793.25 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 3 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,781 F3 · shares: Represents withholding of shares of Company common stock to satisfy exercise price and tax liability associated with exercise of stock options shown above. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionCommon Stock | 7,096 | $37.74 | $267,803.04 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 2 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 17:40 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionCommon Stock | 3,500 | $37.74 | $132,090.00 |
DisclosureSEC source: 0001179110-16-030772 · edgar.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 17:23 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionRestricted Stock Units · Derivative | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-029613 · edgar.xml · derivative · entry 2 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. F2 · derivative.exercise_date: On August 31, 2014, the reporting person was granted 20,000 restricted stock units, which vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17). F2 · derivative.expiration_date: On August 31, 2014, the reporting person was granted 20,000 restricted stock units, which vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17). Read SEC document |
| September 09, 2016 Filed Sep 13, 2016 17:23 UTC | ALERE INC. ALR · Entity 172772 | Exercise / conversionCommon Stock | 6,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-16-029613 · edgar.xml · nonDerivative · entry 1 Chiniara Ellen · CIK 0001398764 · GC, Chief Ethics Officer&Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Vesting of shares under the Alere 2010 Stock Option and Incentive Plan was suspended from March 1, 2016 until two business days after Alere's SEC filings became current. Shares vested on September 9, 2016 represent shares that otherwise would have vested during the suspension period. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.